BioCentury
ARTICLE | Clinical News

Endometrial Regenerative Cells: Phase I/II started

July 23, 2012 7:00 AM UTC

Medistem began an open-label, U.S. Phase I/II trial to evaluate 50 million, 100 million and 200 million intramuscular ERC in about 15 patients with CLI. ERCell has exclusive rights to ERC from Mediste...